Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges

Hanquet, Germaine; Lernout, Tinne; Vergison, Anne; Verhaegen, Jan; Kissling, Esther; Tuerlinckx, David; Malfroot, Anne; Swennen, Béatrice; Sabbe, Martine

doi:10.1016/j.vaccine.2011.02.016

Cited by 43 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To quantify the effect of PCV13 introduction, we used a potential outcomes modeling approach 25,26 with advantages over “before-after” comparisons. 2 First, rates of serotypes 19A and 7F were increasing in ABCs areas before PCV13 introduction.…”

Section: Discussionmentioning

confidence: 99%

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

Moore

Link‐Gelles

Schaffner

et al. 2015

The Lancet Infectious Diseases

633

513

View full text Add to dashboard Cite

SUMMARY Background In 2000, 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in the U.S. and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and modest increases in non-PCV7-type IPD. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the U.S. immunization schedule. We evaluated the effect of PCV13 use in children on IPD in children and adults in the U.S. Methods We used laboratory- and population-based data on incidence of IPD from CDC’s Emerging Infections Program / Active Bacterial Core surveillance in a time-series model to estimate the impact of vaccination. Cases of IPD during July 2004–June 2013 were classified as being caused by the PCV13 serotypes against which PCV7 has no effect (PCV13/nonPCV7). Findings Compared with incidence expected among children <5 years old if PCV7 alone had been continued, incidence of IPD overall and IPD caused by PCV13/nonPCV7 serotypes declined by 64% (95% interval estimate [IE] 59–68 %) and 93% (95%IE 91–94), respectively, by July 2012–June 2013. Among adults, incidence of IPD overall and PCV13/nonPCV7-type IPD also declined by 12–32% and 58–72%, respectively, depending on age. In all age groups, reductions were driven principally by changes in incidence of serotypes 19A and 7F. We estimate that over 30,000 cases of IPD and 3,000 deaths were averted in the first 3 years following PCV13 introduction. Interpretation PCV13 has reduced IPD among all ages when used routinely in children in the U.S. Serotypes 19A and 7F, which emerged after PCV7 introduction, have been effectively controlled.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

Moore

Link‐Gelles

Schaffner

et al. 2015

The Lancet Infectious Diseases

633

513

View full text Add to dashboard Cite

show abstract

“…This serotype became an increasingly common cause of disease in some countries following introduction of PCV-7 lacking 19A antigen. [30][31][32]41,42 Our multiyear surveillance platform may facilitate further understanding about 19A, including possible cross-protection by 19F, 43 in a developing country using PCV-10.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of Invasive Pneumococcal Disease in Bangladeshi Children Before Introduction of Pneumococcal Conjugate Vaccine

Saha

Hossain

Islam

et al. 2016

The Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…Because IPD rates were changing before PCV7 introduction in some sites, we used the pre-PCV7 IPD trends (excluding the year of introduction) to predict future years’ IPD rates, absent PCV7 use [15],[16]. We used Poisson regression to model expected rates of VT, NVT, and overall IPD absent PCV7 introduction.…”

Section: Methodsmentioning

confidence: 99%

Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

et al. 2013

View full text Add to dashboard Cite

show abstract

Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges

Cited by 43 publications

References 28 publications

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

Epidemiology of Invasive Pneumococcal Disease in Bangladeshi Children Before Introduction of Pneumococcal Conjugate Vaccine

Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

Contact Info

Product

Resources

About